Medizinisches Versorgungszentrum MediaVita GmbH Muenster

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer	CCCA Assessed by Ki67 Drop Below <2.7% From Baseline	Recruiting	Phase 2	2025-04-02		NCT06607757

Clinical trials